Lantheus Holdings, Inc. (LNTH) News
Follow Lantheus Holdings, Inc. (LNTH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 28 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
PharmaLogic Agrees to Buy Lantheus CDMO Business and New Jersey Facility
PharmaLogic Holdings agreed to acquire Lantheus Holdings’ contract development and manufacturing organization business and its Springfield, New Jersey, facility.
MNA | Nov 09, 2026, 10:37 PM UTC
M
PharmaLogic to Acquire Lantheus CDMO Business and New Jersey Facility
PharmaLogic says the acquisition will expand U.S. therapeutic manufacturing capacity and create a transatlantic CDMO platform focused on radioligand therapies.
EQUITY | Nov 09, 2026, 09:05 PM UTC
L
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:21 PM UTC
L
Lantheus Reports Results for Quarter Ended September 30
EARNINGS | Nov 05, 2026, 04:24 PM UTC
M
Lantheus Reports Higher Q3 Adjusted Earnings and Revenue
EQUITY | Nov 05, 2026, 01:02 PM UTC
M
Lantheus Holdings reports Q3 earnings
Lantheus Holdings reported third-quarter results.
EQUITY | Nov 05, 2026, 12:45 PM UTC
M
Lantheus Reports Third-Quarter 2026 Financial Results
Worldwide revenue was $389.9 million in the third quarter of 2026.
EQUITY | Nov 05, 2026, 12:10 PM UTC
L
Lantheus Receives FTC Second Requests in Merger Review
Lantheus received FTC requests for additional information in its merger review and still expects the deal to close in the first half of 2027.
MNA | Oct 22, 2026, 11:33 AM UTC
M
Banks vie to provide $4.25 billion financing for Lantheus deal
Banks are competing to provide $4.25 billion in debt financing for a deal involving Lantheus, Bloomberg News reports. Reuters says it has not verified the story.
MNA | Oct 15, 2026, 11:47 AM UTC
L
Lantheus Holdings, Inc. (LNTH) Wins CMS TPT Status for PYLARIFY TruVu
Lantheus said CMS granted Transitional Pass-Through status and a permanent HCPCS code for PYLARIFY TruVu, both effective Oct 1, 2026, enabling separate reimbursement in hospital outpatient settings.Material DetailsContex
NEWS | Sep 30, 2026, 12:32 PM UTC
L
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -
NEWS | Sep 30, 2026, 12:31 PM UTC
L
Lantheus Holdings, Inc. (LNTH) Doses First Patient in SPARROW Phase 2/3 Registrational Trial
Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational trial of GRPR-targeted PET agent LNTH-2401 in prostate cancer, with Phase 3 planned to enroll ~400 participants and assess sensitivity and specifici
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") NASDAQ
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Weekly Recap: BRAVNETSA approved and HSR reset to Oct 21, 2026
Lantheus Holdings Inc (NASDAQ:LNTH) won FDA approval for BRAVNETSA (lutetium Lu-177 dotatate) as bioequivalent to LUTATHERA for adult GEP—NETs and plans a staged launch centered on supply, pricing and patient access whil
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
LNTH - Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
LNTH - Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of
REGULATION | Sep 22, 2026, 12:00 PM UTC
H
Lantheus wins FDA approval for TAUKLARIFY™ F-18 tau PET agent
Lantheus (LNTH) announces FDA approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-labeled tau PET imaging agent for Alzheimer’s disease.
REGULATION | Aug 14, 2026, 12:00 PM UTC
L
LNTH - Lantheus Reports Second Quarter 2026 Financial Results
LNTH - Lantheus Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:01 AM UTC
H
Lantheus Holdings Enters Merger Agreement with Curium
Lantheus Holdings merges with Curium at $102.50 plus CVR
MNA | Aug 04, 2026, 12:05 PM UTC
H
Lantheus: Deal Financing Via Debt, Equity
Lantheus deal to be financed by debt and equity
MNA | Aug 03, 2026, 11:32 AM UTC
H
Curium to Merge with Lantheus for $114.50/Share
Curium merges with Lantheus in $8B deal
MNA | Aug 03, 2026, 11:31 AM UTC
H
Lantheus to Merge with Curium
Lantheus merging with Curium
MNA | Aug 03, 2026, 11:31 AM UTC
H
LNTH Halts on Pending News
LNTH trading halted pending news
EQUITY | Aug 03, 2026, 11:26 AM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
L
Curium in talks to acquire Lantheus in roughly $7B deal, Bloomberg says
Curium in talks to acquire Lantheus in roughly $7B deal, Bloomberg says
EQUITY | Jul 27, 2026, 09:28 PM UTC
M
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.’s (NASDAQ: LNTH ) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic ima
REGULATION | Jun 29, 2026, 01:51 PM UTC
H
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Concentrix Corp. (NASDAQ: CNXC ) to post quarterly earnings at $2.6
EARNINGS | Jun 29, 2026, 06:34 AM UTC
H
LNTH: FDA Issues CRL
Lantheus Holdings shares are trading lower after the FDA issued a Complete Response Letter regarding its New Drug Application For LNTH-2501
EQUITY | Jun 26, 2026, 08:05 PM UTC
M
LNTH Receives FDA Letter
Lantheus Holdings receives FDA Complete Response Letter for LNTH-2501 due to manufacturing facility issues
REGULATION | Jun 26, 2026, 08:02 PM UTC